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Abstract The blood pressure (BP) J-curve debate started in
1979, and we still cannot definitively answer all the ques-
tions. However, available studies of antihypertensive treat-
ment provide strong evidence for J-shaped relationships
between both diastolic and systolic BP and main outcomes
in the general population of hypertensive patients, as well as
in high-risk populations, including subjects with coronary
artery disease, diabetes mellitus, left ventricular hypertro-
phy, and elderly patients. However, further studies are still
necessary in order to clarify this issue. This is connected to
the fact that most available studies were observational, and
randomized trials did not have or lost their statistical power
and were inconclusive. Perhaps only the Systolic Blood
Pressure Intervention Trial (SPRINT) and Optimal
Blood Pressure and Cholesterol Targets for Preventing
Recurrent Stroke in Hypertensives (ESH-CHL-SHOT)
will be able to finally answer all the questions. Accord-
ing to the current state of knowledge, it seems reason-
able to suggest lowering BP to values within the 130–
139/80–85 mmHg range, possibly close to the lower
values in this range, in all hypertensive patients and to
be very careful with further BP level reductions, espe-
cially in high-risk hypertensive patients.
Keywords Blood pressure . J-curve . High-risk
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Introduction
Arterial hypertension is the number one direct cause of
death in the world and the third cause of disability. Through
the metabolic syndrome, it is closely related to other major
health threats of modern society such as inactivity, obesity,
hyperglycemia and dyslipidemia [1–3]. About 54 % of
strokes and 47 % of ischemic heart disease cases worldwide
are attributable to high blood pressure (BP), and hyperten-
sion is present in approximately 69 % of patients with a first
myocardial infarction (MI), in approximately 77 % of
patients with a first stroke, in approximately 74 % of
patients with chronic heart failure (HF) and in 60 % of
patients with peripheral arterial disease [3–5].
In 2009 the reappraisal of the guidelines of the European
Society of Hypertension (ESH) addressed the issue of the so-
called J-curve (or U-curve) and the clinical implications stem-
ming from this phenomenon for the first time [6, 7]. The
recommendations also suggest lowering the systolic BP
(SBP)/diastolic BP (DBP) to values within the 130–139/80–
85 mmHg range, possibly close to the lower values in this
range, in all hypertensive patients [6]. This was a result of the
publication of several important studies and post hoc analyses
concerning intensive BP lowering in patients from high-risk
groups, including especially hypertensive subjects with dia-
betes (DM) and coronary artery disease (CAD) [8–10]. The
recent data indicate that problems with intensive BP reduction
can also be present in the elderly, in patients with left ventricle
dysfunction and after stroke/transient ischemic attack (TIA)
[11–13]. These data challenge the current belief that, in
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patients at cardiovascular (CV) risk, a decrease in BP to below
120/70-75 mmHg is associated with a reduction of CVevents;
on the contrary, they suggest an increase in the risk of adverse
CVevents [6–13].
This review aims to answer questions about the mecha-
nisms involved in the J-curve phenomenon, to determine the
patient groups that may potentially be at the highest risk and
finally to determine whether there is strong enough evidence
to confirm that there is such a phenomenon in hypertensive
patients.
Search Strategy
We searched using the electronic databases MEDLINE
(1966–August 2012), EMBASE and SCOPUS (1965–
August 2012), and DARE (1966–August 2012). Addition-
ally, abstracts from national and international cardiovascular
meetings were searched. Where necessary, the relevant
authors were contacted to obtain further data. Retrospective
studies, as well as small studies with fewer than 100
patients, were excluded from the review. The main data
search terms were: blood pressure, diabetes, hypertension,
intensive (aggressive) hypotensive therapy, J-curve, therapy
and treatment.
What is the J-curve Phenomenon?
The discussion on the J-curve (U-curve) phenomenon started
in 1979 when Stewart presented the results of studies con-
ducted in 169 patients with severe hypertension [14]. He
noticed that the relative risk of MI was over five-fold higher
in individuals who had achieved a DBP reduction <90 mmHg
compared with a BP in the range of 100–109 mmHg [10, 14].
Subsequent reports, published in the 1980s and 1990s, con-
firmed those observations [10, 15]. Therefore, the J-curve
phenomenon is defined as the shape of the relationship be-
tween BP and the risk of CV morbidity and mortality, which
means that the risk of CVevents may increase at both too high
and too low levels of BP. Hypertension specialists are also in
agreement that there is a lowest value of BP (nadir), which
represents a point at which BP is too low tomaintain perfusion
of vital organs, particularly the heart [10].
Initially, the J-curve phenomenon was described for DBP
in patients with CAD [10, 16]. Most coronary perfusion
occurs during diastole, and DBP lowering results in low
coronary perfusion pressure and dilation of coronary micro-
vessels [10, 17]. After the maximal vasodilation has been
achieved, further reduction of perfusion pressure results in
decreased coronary blood flow. In patients who have stenot-
ic lesions of large coronary arteries [e.g., with DM, CAD
and left ventricle hypertrophy (LVH), where myocardial O2
consumption is essentially increased), an upward shift of
perfusion pressure is required to maintain distal flow past
the stenosis, and therefore there is much less tolerance of
DBP reduction [17, 18]. Therefore, a further fall in DBP in
these patients may lower the coronary perfusion pressure to
a critical level, intensifying ischemia and potentially causing
a CV event [17]. Finally, it is also important to mention that
low coronary flow is associated with increased blood vis-
cosity and platelet adhesiveness, predisposing to intracoro-
nary thrombosis and MI [10, 17–20].
Recently, there have also been some data on the J-curve
phenomenon for SBP, although the majority of studies focus
on DBP. This is connected to the fact that only in isolated
cases is it possible to achieve SBP values low enough to
potentially pose any threat to the patient. However, it is
worth noting that since lowering the DBP is closely associ-
ated with lowering SBP, the problem may arise of patients
with high pulse pressure while their SBP values are still high
but DBP low. The current recommendation is that the SBP
should still be lowered without concern for the DBP, since it
is the high SBP that is most predictive in terms of CV event
occurrence [10, 21, 22].
Despite increasing evidence for the J-curve, there has
also been a debate on possible sources of bias concerning
this phenomenon (this has been previously discussed [10]),
which is especially connected to the intrinsic biases in the
identification of a J-shape of risk factor relationships [10].
Hypertension as a primary risk factor (and the beginning of
the ‘cardiovascular disease continuum’) may be negatively
confounded with other residual risk factors. Thus, it is not
surprising that the J-curve phenomenon might also occur in
the analyses of cholesterol and low density lipoprotein cho-
lesterol (LDL-C) (‘lipid paradox’), body mass index (BMI;
‘obesity survival paradox’), glucose or uric acid [10, 23,
24]. One should note that if this risk confounding combines
with effect modification between the primary and residual
risk factors, then the aggregate effect is a nonlinear distor-
tion of the risk factor relation, which may produce an
apparent threshold or J-curve relationship [10]. This was
confirmed in a large collaborative meta-analysis of 102
prospective studies that enrolled a total of almost 700,000
persons without a history of vascular disease or diabetes at
baseline, where a J-shaped relationship was observed both
between SBP and coronary heart disease (CHD; nadir:
130 mmHg) and between CV events and other major risk
factors, including fasting blood glucose and total and non-
high-density lipoprotein (HDL) cholesterol [25].
Optimal BP in High CV Risk Patients
Apart from CAD and DM patients, the J-curve phenomenon
has been observed in studies including high-risk
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hypertensive patients. On the other hand, there are also
studies that did not confirm the phenomenon. In the Swed-
ish Behandla Blodtryk Bättre (BBB)–Treat Blood Pressure
Better Study [26], the authors compared the effects of in-
tensive hypotensive therapy aimed at a reduction of DBP to
<80 mmHg with the maintenance of DBP values in the
range of 90-100 mmHg (standard treatment) in hypertensive
patients and did not find an increased occurrence of adverse
effects in patients with DBP <80 mmHg [26]. In the Hyper-
tension Optimal Treatment (HOT) study [27], the patients
(n018,790) were randomized into three groups that aimed at
achieving DBP values ≤90, ≤85 or ≤80 mmHg. The authors
showed that the lowest risk of CV events was observed at a
DBP of 82.6 mmHg, while a decrease of DBP below this level
had no effect on the reduction of risk of CV complications.
The study also did not demonstrate any increase in CV event
incidence in the group of patients with DBP <70 mmHg [27].
At this point it is, however, necessary to emphasize that the
HOT study had some important limitations (it has been previ-
ously discussed [10]). Due to the lack of detailed data on the
group of 3,080 patients with cardiac ischemia, the final con-
clusion concerning the safety of intensive DBP lowering was
called into question [10, 28]. The inclusion of those data
suggested the existence of a J-curve relationship between the
incidence of CVevents (MI) and the DBP values (<80mmHg)
in patients with CAD and the absence of such a relationship in
a group of individuals not suffering from CAD [10, 28, 29]
(Table 1).
In the Valsartan Antihypertensive Long-term Use Evalu-
ation (VALUE) trial [30], patients aged ≥50 years with
treated or untreated arterial hypertension, with high CV risk,
were included and randomized to two parallel arms, receiv-
ing either valsartan (80-160 mg/day) or amlodipine (5-
10 mg/day). The lowest risk of CV events was observed in
the 120-130 mmHg SBP range (nadir), while a further
reduction was associated with a significant increase in car-
diac complications (CVD events). On the other hand, it must
be emphasized that there were only a few people at the
lower end of SBP values [30, 31] (Table 1).
Similar results were obtained in the Ongoing Telmisartan
Alone and in Combination with Ramipril Global Endpoint
Trial (ONTARGET) [32], where 25,588 high-risk patients
with known atherosclerotic disease or diabetes with vascular
damage (9,603 patients) were included. The authors showed
that achieving a significant reduction of SBP >130mmHgwas
associated with a significantly higher risk of the occurrence of
a composite endpoint comprising CV mortality (nadir:
130 mmHg) and MI (nadir: 126 mmHg). For any level of
SBP achieved, the highest risk of a CV event or stroke was
seen in participants with the DBP ≤72 mmHg [32]. The
secondary analysis of ONTARGET compared the benefits
and risks of treatment aiming to reach BP targets of <140/90
vs. <130/80 mmHg for cardiovascular complications (CVD,
renal events and stroke) [33]. The authors showed that CV
events were reduced by increasing the frequency of BP control
to <140/90, but not to <130/80 mmHg. At the same time, no J-
curve relationship was observed between the lowering of SBP
and an increase in stroke risk (achievement of lower BP goals
appeared to be useful in stroke prevention) [33, 34] (Fig. 1a
and Table 1).
The results of the VALUE and ONTARGET trials were not
confirmed in the Studio Italiano Sugli Effetti CARDIOvasco-
lari del Controllo Della Pressione Arteriosa SIStolica (CAR-
DIO-SIS) study [35], which aimed at evaluating whether strict
control of SBP (target value <130 mmHg; n0558), as com-
pared to the standard one (target value <140 mmHg; n0553)
did reduce the risk of LVH and serious CV events in patients
with hypertension but no diabetes and with high CV risk [35].
After 2 years of follow-up, in the strict control group as
compared to the typical control, there was a significantly
lower risk of total CVevents, cardiac revascularization, recent
atrial fibrillation and LVH, as well as comparable risk of total
death, MI, hospitalization due to HF, stroke or transient ische-
mic attack (TIA). The results of the CARDIO-SIS study did
not confirm the J-shaped relationship; however, it is important
to remember the limitations of this trial: its relatively small
size, short duration of follow-up and use of an intermediate
endpoint (ECG-LVH) as the primary outcome [10, 17, 35].
J-curve in CAD Patients
Patients with CAD are at increased risk of ischemic events
beyond a certain DBP [13, 17–20]. In the Framingham
Heart Study (FHS) [16], the authors observed an age- and
sex-independent J-curve relation for DBP and CHD deaths
in patients with MI (but not for low-risk subjects without
MI), which was independent of left ventricular function and
antihypertensive treatment [16]. These observations have
been confirmed in many subsequent trials, the most impor-
tant one being the International Verapamil SR-Trandolapril
Study (INVEST) [36], where CAD patients undergoing
intensive hypotensive treatment because of arterial hyper-
tension (verapamil 240 mg/day or atenolol 50 mg/day, with
the possibility of adding trandolapril at a starting dose of
2 mg/day as a second-line drug) were included. The authors
found a J-shaped relationship with a nadir of 119/84 mmHg
(129/74 mmHg after adjustment for time to primary
outcome) between both SBP and DBP and all-cause
mortality and MI in both treatment groups. DBP lower-
ing to <80 mmHg resulted in a significant increase in
the risk of MI as compared with patients with higher
DBP. However, the risk of MI was also observed in
individuals with DBP <60 mmHg (as high as 14 %; for
comparison, for DBP ≥110 mmHg it rose by 13 %) [8,
36] (Table 1).
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The Treating to New Targets (TNT) [37] study evaluated
the impact of intensive hypolipidemic treatment (atorvasta-
tin 80 vs. 10 mg) on the occurrence of a first serious CV
event in patients with stable CHD and a baseline level of
LDL-C <130 mg/dl (3.4 mmol/l). The final analysis
revealed a significant correlation between CV events (all-
cause mortality, CV mortality, nonfatal MI and stroke) and
an excessive lowering of DBP (nadir: 79.8 mmHg) and SBP
(nadir: 140 mmHg) (p<0.0001 for all). However, the risk of
occurrence of a primary endpoint rose once the SBP reached
110 mmHg and DBP 60 mmHg [hazard risk (HR) 3.1 and
3.3, respectively] [10, 37] (Fig. 1b and Table 1). This was
Table 1 Summary of the most important studies in which a J-curve relationship was observed between either DBP or SBP and adverse outcomes
Study Year No. of
participants (n)




D'Agostino et al. (Framingham Heart
Study) [16]
1991 5,209 Yes Yes - - - - 75 -
Systolic Hypertension in The Elderly
Program (SHEP) study [56]
1991 4,736 Yes - - - Yes - 70 (55)1 -
Hypertension Optimal Treatment (HOT)
Study [27]
1998 3,080 Yes Yes - - - - 80 -
Vokó et al. (The Rotterdam Study) [55] 1999 7,983 Yes - - - Yes - 65 -
Pastor-Barriuso et al. (Second National
Health and Nutrition Examination
Survey) [57]
2003 7,830 - - - - Yes - 80-90 -
International Verapamil SR-Trandolapril
Study (INVEST) [36]
2003 22,576 - Yes - - - - 84 119
Systolic Hypertension in Europe
(Syst-Eur) Trial [58]
2004 4,583 Yes Yes - - Yes - 70 -
Valsartan Antihypertensive Long-term
Use Evaluation (VALUE) trial [30]
2004 15,245 Yes - - - Yes - 78 120–130
Irbesartan Diabetic Nephropathy Trial
(IDNT) [47]
2005 1,590 - - Yes - - Yes 85 120
Oates et al. [62] 2007 4,071 - - - - Yes - 89 139
Ongoing Telmisartan Alone and in
Combination with Ramipril Global
Endpoint Trial (ONTARGET) [32]
2009 25,588 Yes Yes Yes - - - 72 126–130
Treating to New Targets (TNT) [37] 2009 10,001 Yes Yes - - - - 79.8 (60-70)2 140 (110-120)2
Agarwal et al. [71] 2009 218 - - - - - Yes 70 -
PRavastatin Or atorVastatin Evaluation
and Infection Therapy-Thrombolysis
In Myocardial Infarction (PROVE
IT-TIMI) 22 trial [39••]
2010 4,162 Yes Yes - - - - 70 110
International Verapamil SR-Trandolapril
Study (INVEST) [43••]
2010 6,400 - Yes Yes - - - - 115
International Verapamil SR-Trandolapril
Study (INVEST) [63•]
2010 2,180 - Yes - - Yes - 70 140
Action to Control Cardiovascular Risk
In Diabetes – Blood Pressure Arm
(ACCORD-BP) [44••]
2010 4,733 Yes - Yes - - - - 120 (119.3)3
Ogihara et al. [61] 2011 1,500 - - - - Yes - - 120
Ongoing Telmisartan Alone and in
Combination with Ramipril Global
Endpoint Trial (ONTARGET) [33]
2011 12,554 Yes Yes Yes - - - 80 130
Digitalis Investigation Group
(DIG) [66•]
2011 7,788 - - - Yes - - - 120
Beta-Blocker Evaluation of Survival
Trial (BEST) [67]
2011 2,706 - - - Yes - - -
Secondary Manifestations of Arterial
Disease (SMART) study [40••]
2012 5,788 Yes Yes - - - - 82 143
Losartan Intervention For Endpoint
reduction in hypertension study
(LIFE) [65]
2012 9,193 - - - Yes - - - 130
Vamos et al. [50•] 2012 126,092 - Yes Yes - - - 70 110
CAD coronary artery disease; DM diabetes mellitus; LVH left ventricular hypertrophy; CKD chronic kidney disease; DBP diastolic blood pressure;
SBP systolic blood pressure
1 The relative risk of composite cardiovascular events was close to two-fold greater for DBP <55 mmHg; 2 For the primary endpoints; 3 The SBP
level below which an increase in therapy-related adverse events (orthostatic hypotension, hyperkalemia, syncope, bradycardia, arrhythmia or renal
function impairment) was observed
Curr Hypertens Rep (2012) 14:556–566 559
also confirmed in the subanalysis of the TNT trial, which
showed that in patients with CAD, a low BP (<110-120/
<60-70 mmHg) portended an increased risk of future CV
events (except stroke). The authors also noted that for the
BP level (nadir) of 146.3/81.4 mmHg the risk of CV events
was the lowest [38]. It is worth noting that this study
involved on-treatment BP levels and included a population
that was on statins with aggressive CV factor modification
[17, 38] (Table 1).
In the analysis of the PRavastatin Or atorVastatin Evalu-
ation and Infection Therapy-Thrombolysis In Myocardial
Infarction (PROVE IT-TIMI) 22 trial, the authors evaluated
4,162 patients with acute coronary syndrome (ACS) ran-
domized to pravastatin 40 mg or atorvastatin 80 mg [10,
39••]. A nonlinear Cox proportional hazards model showed
a nadir of 136/85 mmHg at which the incidence of primary
outcome was lowest. The curve was relatively flat for sys-
tolic BPs of 110 to 130 mmHg and diastolic BPs of 70 to
90 mmHg. On the basis of these results, the authors suggest
that low BP, especially <110/70 mmHg, may be dangerous
for patients with ACS [10, 39••] (Table 1).
These J-curve data from randomized trials are supported
by findings of the recently published Secondary Manifesta-
tions of Arterial Disease (SMART) study [40••]. A total of
5,788 patients with symptomatic vascular disease were
followed up for the occurrence of new vascular events
(MI, stroke or vascular death) and all-cause mortality. Dur-
ing a median of 5.0 years, 788 patients experienced a new
vascular event, and 779 died. The relationship between
mean baseline SBP, DBP, or pulse pressure and the occur-
rence of vascular events followed a J-curve with increased
event rates above and below the nadir of 143/82 mmHg. A
similar nonlinear relationship was found for DBP and all-
cause mortality [40••] (Table 1).
Very interesting results were observed in the most recent
meta-analysis aiming to evaluate the BP targets in patients
with CAD [41]. Fifteen randomized clinical trials enrolling
66,504 participants were included. The authors found that the
intensive BP lowering group (≤135 mmHg) was associated
with a 15 % decrease in HF rate and 10 % decrease in stroke
rate, and the more intensive BP lowering group (≤130 mmHg)
was associated with a reduction in MI and angina pectoris.
They concluded that in patients with CAD, intensive SBP
control to ≤135 mmHg and possibly to ≤130 mmHg was
associated with a modest reduction in stroke and HF, but at
the expense of hypotension (10.5 % risk) [41]. These results
are interesting, but they add very little to the current knowl-
edge on the J-curve in CAD hypertensive patients, as the
authors did not analyze the outcomes associated with the
reduction of BP levels below 120 or even 110 mmHg, they
focused only on SBP, and finally the included studies were
very heterogeneous, with different patients, therapies, study
durations and endpoints [41].
Optimal BP Level in Diabetic Patients
Diabetes increases the risk of CVD almost three-fold irre-
spective of the SBP values. However, the current ESH
guidelines (2009) changed the hitherto recommended tar-
geted level of BP in DM patients, i.e., SBP<130 mmHg,
and suggested that the only confirmed therapeutic target was
lowering the BP to below 140/90 mmHg (optimally in the
range 130-139/80-85 mmHg) [6, 10, 42].
The above has been supported by recent studies, includ-
ing a retrospective analysis of the INVEST study [43••] in
which the patients were divided into three groups depending
on the achieved BP: (1) those who had not reached the
control level (SBP ≥140 mmHg), (2) those who had reached
the standard control level (SBP <130-140 mmHg) and (3)
those on intensive BP control (SBP ≤130 mmHg) [10, 42].
In patients with non-controlled BP, the risk of death, MI or
stroke was as much as 50 % higher compared to those with
controlled BP (HR 1.46; p<0.0001). The authors also ob-
served increased risk of death due to any cause – about 8 %
after 30 months and 5 years after the study [adjusted HR:
1.20 (p00.06) and 1.15 (p00.04), respectively] in patients
with intensively controlled BP. Additional analyses revealed
Fig. 1 J-curve in the (a) ONTARGET ([10] modified according to [32,
33]) and (b) TNT ([10] modified according to [37]) studies
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that this risk was caused by a higher incidence of death in
patients with SBP below 115 mmHg [43••]. Although the
above data could have been burdened with some errors (i.e.,
the lack of initial division into groups with different target
BP values or lack of information on how the patients with
the lowest SBP had been managed), they confirm the risk
associated with excessively intensive lowering of BP in DM
patients [10] (Table 1).
The Action to Control Cardiovascular Risk In Diabetes –
Blood Pressure Arm (ACCORD-BP) study [44••] was
designed to evaluate the impact of treatment aimed at inten-
sive lowering of SBP to <120 mmHg (compared to standard
therapy) on the incidence of CV events in 4,733 DM
patients. The study enrolled high-risk DM patients: aged
≥40 and with coexisting CVD; or aged ≥55 with marked
atherosclerosis, albuminuria, and LVH; or with at least two
risk factors for CVD: dyslipidaemia, arterial hypertension,
smoking or obesity [44••]. After a year of treatment, the
mean SBP was 119.3 mmHg in the group managed inten-
sively and 133.5 mmHg in the group on standard therapy,
while the mean DBP values were 64.4 and 70.5 mmHg,
respectively [10, 44••]. The primary endpoint, comprising
nonfatal MI or stroke, or death due to CV causes, occurred
in 445 patients (1.87 % per year in the group on intensive
treatment compared with 2.09 % of those on standard ther-
apy; p00.20). In addition, there were 294 deaths due to any
cause (1.28 % in the intensive therapy group vs. 1.19 % in
the standard treatment group; p00.55) and 118 due to car-
diovascular causes (0.52 % vs. 0.49 %, respectively; p0
0.74) [10, 44••]. The incidence of stroke was significantly
higher in the group receiving standard treatment (0.53 % vs.
0.32 %; p00.01); a similar relationship was found for non-
fatal stroke (0.30 % vs. 0.47 %; p00.03) [10, 44••]. It was
concluded that intensive hypotensive therapy did not signif-
icantly reduce the incidence of primary endpoints or the
majority of secondary endpoints; however, it was associated
with a significant reduction in the total number of strokes
(by 41 %; HR 0.59; 95 % CI, 0.39–0.89; p00.03) and
nonfatal strokes (by 37 %) [10, 44••, 45] (Table 1).
As was previously discussed [10], the interpretation of
ACCORD-BP results is neither easy nor obvious, since the
group receiving standard treatment exhibited a lower (by
over 50 %) rate of events than expected initially, and in the
intensive therapy group, the incidence of adverse complica-
tions of treatment (orthostatic hypotension, hyperkalemia,
syncope, bradycardia, arrhythmia or renal function impair-
ment) was significantly increased (3.3 % vs. 1.3 %) [44••,
45]. Two important conclusions can be drawn on the basis
of the ACCORD study: (1) it is important to define the
group of patients in whom significant BP reduction could
be particularly dangerous and – on the other hand – those
with a high risk of stroke who could benefit most from an
intensive hypotensive therapy, and (2) lowering of SBP to
below 115 mmHg (also as a result of INVEST study anal-
ysis) may be dangerous, and hence the absolute safety limit
in DM patients should be accepted as SBP in the range of
110-115 mmHg [10, 43••, 44••, 45, 46].
Similar results were observed in two other studies: in the
Irbesartan Diabetic Nephropathy Trial (IDNT) [47], DBP
<85 mmHg was associated with a trend to an increase in all-
cause mortality, a significant increase in MI, but a decreased
risk for stroke [47] (Table 1); in the Appropriate Blood
Pressure Control in Diabetes-Normotension (ABCD-NT)
trial [48], SBP <130 mmHg was not associated with a
benefit in the primary outcome (renal dysfunction) or any
other CVoutcome. The active group participants did benefit
from a significant reduction in stroke. A lack of benefits of
lowering the SBP level <130 mmHg in patients with diabe-
tes was also observed in the recent analysis of the ONTAR-
GET trial [49].
The most recent trial not only confirmed the lack of
benefits of lowering the SBP below 130 mmHg, but also
the J-shaped relationship in DM patients [50•]. A total of
126,092 adult patients (age ≥18 years) from the United
Kingdom General Practice Research Database with a new
diagnosis of type 2 diabetes were included. In patients with
CVD, tight control of SBP (<130 mmHg) and DBP
(<80 mmHg) was not associated with improved survival.
Low BP was also associated with an increased risk of all-
cause mortality [50•]. Compared with patients who received
usual control of SBP (130-139 mmHg), the HR of all-cause
mortality was 2.79 (95 % CI 1.74-4.48, p<0.001) for SBP at
110 mmHg. Compared with patients who received usual
control of DBP (80-84 mmHg), the HRs were 1.32 (1.02-
1.78, p00.04) and 1.89 (1.40-2.56, p<0.001) for DBP at 70-
74 mmHg and lower than 70 mmHg, respectively. Similar
associations were found in people without CVD [50•]
(Table 1).
Optimal Blood Pressure in the Elderly
In Europe the average life expectancy at birth has risen from
around 45 years in the 1900s to 65.6 years in 1950-1955 to
75.1 years in 2005-2010, and in the EU (European Union)
27, it is expected to rise to 85.3 years for women and
80.0 years for men [2, 51]. The number of Europeans aged
65+ is expected to increase by 45 % between 2008 and
2030, and even further to over 30 % of the population by
2060 [2, 51–53]. The same situation concerns the US, Japan
and other countries. Therefore, currently we face the chal-
lenge not only to increase the length of life, but also to
improve the quality of therapy and in consequence the
quality of life in the elderly. Recently, there has been exten-
sive discussion on the effective treatment of hypertension in
the elderly population. This is connected to the fact that
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despite the available data we still do not know what the
optimal BP levels are in these patients (or whether we can
observe a J-curve relationship), which drugs are the most
effective and have the fewest therapy-associated adverse
events, and how the hypertension therapy can really prevent
complications, reduce mortality and improve quality of life
[2, 51, 54].
The studies published in the 1990s provided evidence of
J-shaped relationships between DBP and CVD outcomes in
elderly populations [27, 28, 55, 56]. The main aim of both
the observational Rotterdam Study [55] and the Systolic
Hypertension in the Elderly Program (SHEP) study [56]
was the assessment of whether long-term application of
hypotensive treatment in the elderly with isolated systolic
hypertension decreases the incidence of stroke. The authors
of both studies revealed a high risk of stroke occurrence also
in the presence of low DBP values <65 mmHg [10, 55, 56].
The SHEP study also demonstrated that the intensive low-
ering of DBP was a factor predisposing to CV events. The
relative risk of composite CV events was significantly
higher for DBP values <70 mmHg and close to two-fold
greater for DBP <55 mmHg [10, 56]. The association be-
tween low DBP and increased CV risk was also observed in
7,830 white and African-American men and women over
65 years of age who were participants in the Second Na-
tional Health and Nutrition Examination Survey (NHANES
II). Decrease in DBP below approximately 80 to 90 mmHg
was significantly associated with increasing all-cause and
CV mortality [10, 57] (Table 1).
The Systolic Hypertension in Europe (SYST-EUR) study
[58] enrolled patients aged ≥60 years not exhibiting symp-
toms of dementia and with SBP and DBP values of 160-
219 mmHg and ≤95 mmHg, respectively. The study
revealed that lowering of the DBP to ≥55 mmHg did not
result in an increase in death rates due to CVevents, while it
could potentially be associated with a higher death rate due
to non-cardiac causes (HR: 1.15 for DBP of 65-60 mmHg; p
<0.005). The authors also found that in elderly patients with
coexisting CAD, uncontrolled lowering of the DBP was
associated with a higher risk of CV events [HR: 1.17 for
DBP of 65-60 mmHg (nadir: 70 mmHg); p<0.02] [10, 58]
(Table 1).
The Hypertension in the Very Elderly Trial (HYVET)
[59] was designed to resolve all uncertainty about the rela-
tive benefits and risks of antihypertensive treatment in el-
derly populations. In the HYVET trial, 3,845 individuals
aged 80 years and older (mean age 83.6 years) with a
sustained SBP of 160 mmHg or higher were randomized
to indapamide at a dose of 1.5 mg or matching placebo.
Perindopril 2 mg or 4 mg, or matching placebo, was added if
needed to achieve the target BP of 150/80 mmHg [2, 59].
The study was terminated early after a median follow-up of
1.8 years. The authors found that antihypertensive drug
therapy significantly decreased the incidence of the primary
endpoint (fatal or nonfatal stroke) by 30 % (p00.06), as well
as other endpoints – fatal stroke by 39 % (p00.05), all-cause
mortality by 21 % (p00.02), death from CV causes by 23 %
(p00.06) and HF by 64 % (p<0.001) [59]. The achieved BP
in the active treatment group was 143.5/77.9 mmHg com-
pared with 158.5/83.2 mmHg in the placebo group. The
authors did not observe a J-shaped relationship for either
SBP or DBP. However, one should note the important
limitations of the HYVET that reduce its generalizability
to the entire population of very elderly hypertensives, in-
cluding (1) the inclusion of very healthy elderly persons
(only 12 % had a history of CVD), who would likely be
insensitive to a J-curve effect of BP reduction, and (2) the
target SBP <150 mmHg, which failed to ascertain whether
further reduction would have been beneficial for this partic-
ular age group [2, 13, 17, 59].
The Japanese Trial to Assess Optimal Systolic Blood
Pressure in Elderly Hypertensive Patients (JATOS) [60]
compared the effect of moderate intensity SBP reduction
(<140 mmHg) with less intense SBP reduction (140–
160 mmHg) in 4,418 elderly (age 65–85 years) hypertensive
patients. The SBP achieved in these groups differed by
about 10 mmHg (135.9/74.8 vs. 145.6/78.1 mmHg, respec-
tively) after 2 years of follow-up. The authors did not
observe a significant difference in the primary endpoint (a
composite of CVD, cardiac and vascular disease and renal
failure) or secondary endpoints (total deaths and safety
issues), or a J-shaped relationship between achieved SBP
and outcomes, or any added benefits from more aggressive
BP reduction [60]. Similar results were obtained in the
Valsartan in Elderly Isolated Systolic Hypertension
(VALISH) study published in August 2010 [61]. The
authors aimed to establish whether strict BP control
(<140 mmHg) was superior to moderate control
(≥140 mmHg to <150 mmHg) in reducing CV mortality
and morbidity in 3,260 elderly patients with isolated systolic
hypertension [61]. At 3 years, BP reached 136.6/74.8 mmHg
and 142.0/76.5 mmHg, respectively (p<0.001 for both).
The overall rate of the primary composite endpoint was
10.6 per 1,000 patient-years in the strict control group and
12.0 per 1,000 patient-years in the moderate one (HR 0.89;
p00.38). Unfortunately, the study was underpowered to
definitively answer whether strict control was superior to
less stringent BP targets and did not allow an evaluation of
the benefits and risks involved with excess BP reduction
(i.e., existence of a J-curve) [10, 61].
A J-curve relationship in this group of patients was
observed in a retrospective study of veterans aged over
80 years in which the authors found that patients with
DBP >89 mmHg and SBP >139 mmHg had lower mortality
compared to those with lower pressures. This relationship
was observed even after adjustment for demographics, body
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mass index, antihypertensive medication use and co-
morbidities [62]. Very similar results were observed in a
subanalysis of the above-mentioned INVEST trial where
2,180 elderly (>80 years) participants were included [63•].
The authors found age-dependent J-shaped relationships be-
tween on-treatment SBP and DBP and the primary outcome
(all-cause mortality, nonfatal MI or nonfatal stroke). The SBP
nadir increased with increasing age from 110 mmHg in the
patients below 60 to 135 mmHg in the 60 to <70 years group
to 140 mmHg in patients over 70. The DBP nadir was
75 mmHg for those <60 to <80 years and 70 mmHg for the
very old [63•] (Table 1).
The most current studies have also confirmed a need for
caution when lowering BP in elderly patients. Ogihara et al.
investigated whether the J-curve relationship was observed
in a large cohort (n01,500) of elderly Japanese patients
(over 60 years) [64]. At 3 years, the authors showed that
the relationship between BP and the incidence of CV events
revealed that patients with SBP of less than 120 mmHg had
a higher incidence of CV events compared with those with
an SBP of 120-139 mmHg [64] (Table 1).
Blood Pressure Targets in LVH Patients
In the subanalysis of the Losartan Intervention For Endpoint
reduction in hypertension study (LIFE) [65], the authors
evaluated the risk of stroke, MI, CV death, the composite
endpoint of these events and all-cause mortality in relation
to in-treatment SBP just prior to an event in 9,193 hyper-
tensive patients with LVH randomly assigned to losartan- or
atenolol-based treatment. Patients with in-treatment SBP
≤130 mmHg and SBP between 131 and 141 mmHg were
compared with the group with in-treatment SBP
≥142 mmHg [65]. The authors found that SBP ≤130 mmHg
was not associated with lower CV risk (in comparison to the
group with SBP of 131 to 141 mmHg) and was associated
with a significantly increased (29 %) risk of death (HR 1.29,
95 % CI 1.06-1.58) and a trend towards increased CV
mortality (HR 1.28, 95 % CI 0.97-1.69) [65]. These out-
comes were independent of achieved DBP and treatment
modality [65]. Similar to findings in diabetic hypertensive
patients, these data do not support treating patients with
ECG-LVH to lower SBP goals in order to prevent CVD
outcomes and death [10, 13, 17] (Table 1).
Similar results were obtained in our trials [66•, 67]. In the
analysis of the Digitalis Investigation Group (DIG) trial
[66•], we studied the impact of baseline SBP on outcomes
in patients with mild to moderate chronic systolic and dia-
stolic HF. During 5 years of follow-up, all-cause mortality
occurred in 35 % and 32 % of matched patients with
SBPs ≤120 and >120 mmHg, respectively. HRs for CV
and HF mortalities associated with SBP≤120 mmHg were
1.15 (p00.031) and 1.30 (p00.006). CV hospitalization
occurred in 53 % and 49 % of matched patients with
SBPs ≤120 and >120 mmHg, respectively (HR 1.13, p0
0.008). HRs for all-cause and HF hospitalizations associated
with SBP ≤120 mmHg were 1.10 (p00.017) and 1.21 (p0
0.002) [66•]. Similar results were observed in the post-hoc
analysis of the Beta-Blocker Evaluation of Survival Trial
(BEST) [67] in patients with chronic HF. At 4-year follow-
up, HF hospitalization occurred in 38 % and 32 % of
patients with SBP ≤120 and >120 mmHg, respectively
(HR 1.33; p00.023) and all-cause mortality in 28 % and
30 %, respectively (HR 1.13; p00.369). On the basis of the
results of these two studies [66•, 67], we concluded that we
should be careful when lowering the SBP below 120 mmHg
in patients with chronic HF, as it might be connected with
adverse CV events (Table 1).
Conclusions
Randomized controlled trials of antihypertensive treatment
provide strong evidence for J-shaped relationships between
both DBP and SBP and main outcomes (all-cause mortality,
CV mortality, nonfatal and fatal MI, HF, stroke) in the
general population of hypertensive patients, as well as
in high-risk populations, including patients with CAD,
DM and LVH, as well as elderly subjects. Data are also
available on a possible J-curve phenomenon in patients
with chronic kidney disease (CKD) [47, 48, 68–71]
(Table 1) and after stroke/TIA (as a result of secondary
prevention therapy) [72, 73, 74•].
Despite many studies in which a J-shaped relationship
was observed, the discussion on the BP J-curve phenome-
non continues. Some authors still dispute the existence of
this phenomenon, claiming among other things that there is
nothing indicating a J-curve mechanism in the ACCORD
BP study [44••], and they suggest that the findings in the
INVEST [36, 43••], VALUE [30], ONTARGET [32, 49]
and other trials might be artifacts caused by the observa-
tional nature of these analyses [10]. It is also emphasized
that the BBB [26], HOT [27], ACCORD BP [44••] and TNT
[37] studies were not originally powered to detect harmful
effects or non-linear relationships between BP and CV
events [10, 75, 76]. Finally, most of the current evidence
supporting the J-curve concept comes from post hoc analy-
ses that are subject to confounding and have obvious limi-
tations: (1) randomization is lost, (2) the numbers of patients
and events in the lowest SBP/DBP group are very small, and
(3) patients in the lowest BP groups markedly differ from
those with higher BP and often are at increased baseline CV
risk [10, 75]. Although these baseline disparities are usually
adjusted by sophisticated statistics, it is important to remem-
ber that statistics cannot entirely correct large between-
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group differences [75]. Finally, the nadir should be similar
in different studies, at least for patients at a comparable level
of CV risk, and a recent review of available data has found
widely different nadirs, ranging from 110 to 169 mmHg for
SBP and from 55 to 94 mmHg for DBP [10, 13, 17, 75],
although most analyses point toward a nadir of 130–140/
70–85 mmHg.
Therefore, further studies are still necessary and might
contribute to the clarification of this issue, especially with
exploration of the J-curve as their primary outcome, with
clear and sufficiently large differences in BP levels; these
will be able to answer many questions, including the effects
of individual antihypertensive agents on the J-curve, the
presence or absence of possible confounding factors, or
the potential reversibility of the J-curve [10, 13]. Perhaps
only the Systolic Blood Pressure Intervention Trial
(SPRINT) [77], the results of which are expected to be
available in 2018, and Optimal Blood Pressure and Choles-
terol Targets for Preventing Recurrent Stroke in Hyperten-
sives (ESH-CHL-SHOT) [74•], which starts recruiting
patients in autumn of this year, will be able to finally answer
all these questions.
According to the current state of of knowledge, it seems
reasonable to suggest lowering of BP to values within the
range 130–139/80–85 mmHg, and possibly close to the lower
values in this range, in all hypertensive patients (according to
current ESH 2009 guidelines) and to be very careful with (and
possibly to avoid) further BP reduction, especially in high-risk
hypertensive patients [6, 10, 13, 75–81].
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